TY - JOUR
T1 - Awareness of the metabolic syndrome in patients with bipolar disorder
T2 - A comparison of US and European psychiatrists
AU - Lecrubier, Yves
AU - Bauer, Michael
AU - Hirschfeld, Robert
AU - Mcelroy, Susan
AU - Suppes, Trisha
N1 - Funding Information:
Dr Bauer has received funding for clinical grants from AstraZeneca Pharmaceuticals, GlaxoSmithK-line, Eli Lilly Research Laboratories, The Stanley Medical Research Institute, and NARSAD. He has served on advisory boards for AstraZeneca Pharmaceuticals, Eli Lilly Research Laboratories, GlaxoS-mithKline, Novartis Pharmaceuticals, Servier, and Wyeth.
Funding Information:
Dr Suppes has received funding or medications for clinical grants from Abbott Laboratories, AstraZeneca Pharmaceuticals, GlaxoSmithKline, JDS Pharmaceuticals, Janssen Pharmaceutica, National Institute of Mental Health, Novartis Pharmaceuticals, Pfizer Inc., The Stanley Medical Research Institute, and Wyeth-Ayerst. He has served on advisory boards for Abbott Laboratories, AstraZene-ca Pharmaceuticals, Eli Lilly Research Laboratories, GlaxoSmithKline, Novartis Pharmaceuticals, and Pfizer Inc., and has been involved in speaking bureaus with AstraZeneca Pharmaceuticals and GlaxoS-mithKline. He has received royalties from Compact Clinical publishers.
PY - 2008
Y1 - 2008
N2 - Introduction. The metabolic syndrome is a relatively new concept still being debated in the US and Europe; little is known about how it is factored into psychiatric treatment decisions. Method. Practicing psychiatrists in the US (n=500) and five European countries (UK, France, Italy, Germany, Spain; n=718) participated in brief online surveys in 2005 and 2006. Results. US psychiatrists were more likely than EU psychiatrists surveyed to view metabolic syndrome as a significant health risk; US respondents reported significantly more bipolar patients who were overweight or obese, but similar percentages of bipolar patients who met criteria for the metabolic syndrome. More US than EU psychiatrists reported monitoring metabolic parameters before and during treatment, and generally were more concerned about bipolar medication adverse effects (AEs). Significantly more US psychiatrists indicated that they were extremely or very concerned about weight gain as an AE. Conclusions. For most surveyed US and EU psychiatrists, metabolic health is an important concern in the treatment of bipolar disorder. US psychiatrists reported more often monitoring metabolic parameters and adjusting treatment if abnormalities become evident, but practices are evolving in the US and EU.
AB - Introduction. The metabolic syndrome is a relatively new concept still being debated in the US and Europe; little is known about how it is factored into psychiatric treatment decisions. Method. Practicing psychiatrists in the US (n=500) and five European countries (UK, France, Italy, Germany, Spain; n=718) participated in brief online surveys in 2005 and 2006. Results. US psychiatrists were more likely than EU psychiatrists surveyed to view metabolic syndrome as a significant health risk; US respondents reported significantly more bipolar patients who were overweight or obese, but similar percentages of bipolar patients who met criteria for the metabolic syndrome. More US than EU psychiatrists reported monitoring metabolic parameters before and during treatment, and generally were more concerned about bipolar medication adverse effects (AEs). Significantly more US psychiatrists indicated that they were extremely or very concerned about weight gain as an AE. Conclusions. For most surveyed US and EU psychiatrists, metabolic health is an important concern in the treatment of bipolar disorder. US psychiatrists reported more often monitoring metabolic parameters and adjusting treatment if abnormalities become evident, but practices are evolving in the US and EU.
KW - Bipolar disorder
KW - Cardiovascular diseases
KW - Metabolic syndrome X
KW - Obesity
KW - Weight gain
UR - http://www.scopus.com/inward/record.url?scp=48249088084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48249088084&partnerID=8YFLogxK
U2 - 10.1080/13651500701827671
DO - 10.1080/13651500701827671
M3 - Article
C2 - 24931657
AN - SCOPUS:48249088084
SN - 1365-1501
VL - 12
SP - 187
EP - 195
JO - International Journal of Psychiatry in Clinical Practice
JF - International Journal of Psychiatry in Clinical Practice
IS - 3
ER -